Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8641 to 8655 of 9024 results

  1. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued Reference number: GID-TA10070

    Technology appraisal guidance
    Discontinued

  2. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  3. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  4. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued Reference number: GID-TA10168

    Technology appraisal guidance
    Discontinued

  5. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

    Technology appraisal guidance
    Discontinued

  6. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    In development Reference number: GID-TA11762 Expected publication date:  28 July 2025

    Technology appraisal guidance
    In development

  7. Lasmiditan for treating acute migraine [ID3759]

    Discontinued Reference number: GID-TA10807

    Technology appraisal guidance
    Discontinued

  8. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  9. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development Reference number: GID-MT567 Expected publication date: TBC

    Medical technologies guidance
    In development

  10. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  11. Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]

    In development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  13. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued Reference number: GID-IPG10142

    Interventional procedures guidance
    Discontinued

  14. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued Reference number: GID-TA11258

    Technology appraisal guidance
    Discontinued

  15. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued Reference number: GID-TA10284

    Technology appraisal guidance
    Discontinued